Rubraca

Chemical Namerucaparib
Dosage FormTablet (oral; 200 mg, 250 mg, 300 mg
Drug ClassInhibitors
SystemFemale reproductive
CompanyClovis Oncology Inc
Approval Year2016

Indication

  • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
  • For the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rubraca (rucaparib) Prescribing Information 2018Clovis Oncology, Inc., Boulder, CO